Swedish pharmaceutical company Moberg Pharma AB (STO:MOB) announced on Thursday that the members of its nomination committee, ahead of the 2019 Annual General Meeting, are Thomas Eklund, chairman of the board of directors of the company; Gillis Cullin, appointed by Östersjöstiftelsen; Fredrik Persson, appointed by Zimbrine Holding and Anders Lundmark.

Together, this nomination committee represents 25.27% of the shares in Moberg Pharma as of 30 September 2018.

Reportedly, in accordance with the resolution of the Annual General Meeting on 15 May 2018, the chairman of the board of directors has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a nomination committee.

These shareholders have been invited to appoint one representative each who, together with the chairman of the board, will comprise the nomination committee. As not all of the company's three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the nomination committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on 15 May 2018.

This nomination committee shall submit proposals for resolution by the 2019 Annual General Meeting pertaining to the election of chairman of the board, fees and composition of the board, auditors' fees and the election of auditors.

Moberg Pharma's 2019 Annual General Meeting will be held in Stockholm on 15 May 2018.